06 July 2021

During this hour-long panel discussion, we explored the variation of perception of what is most critical for the patient during the drug development process. From a range of perspectives we discussed the elements that are controversial and most challenging, especially in extremely novel and innovative interventions.

Facilitated by:
- Marcin Mankowski, Deputy Managing Partner at tranScrip

Speakers included:
- Gilbert Wagener, Senior Vice President & Chief Medical Officer at Ixaka
- Nicholas Johnson, Chief Strategy and Impact Officer at Cell and Gene Therapy Catapult
- Sandy Douglas, Research Group Leader at Jenner Institute
- Wills Hughes-Wilson, Chief Patient Access & Commercial Planning at Mereo BioPharma

You can view all ON Helix 2021 recordings here